DNA Script Appoints Marc Montserrat as CEO, Thomas Ybert Transitions to Chief Scientific Officer
DNA Script, a leader in enzymatic DNA synthesis, has appointed Marc Montserrat as its new Chief Executive Officer, while founding CEO Thomas Ybert, PhD, will shift to the role of Chief Scientific Officer (CSO). This transition emphasizes the company’s commitment to scientific discovery and innovation.
Marc Montserrat brings over 20 years of experience in the biotech and life sciences sectors. He previously co-founded Splice Bio, a genetic medicine company, and held key leadership positions at Ariosa Diagnostics, where he played a crucial role in establishing the prenatal testing market. Montserrat has also contributed to startups like Omniome and Deepcell, enhancing next-generation sequencing and AI-powered single-cell analysis, respectively.
“I am honored to join DNA Script at such a pivotal time,” said Montserrat. “The company has revolutionized DNA synthesis, and I look forward to working with Thomas and our talented team to scale the business and accelerate the development of innovative solutions.”
He added, “Under Thomas’ leadership over the past decade, DNA Script has commercialized a groundbreaking enzymatic DNA synthesis technology, achieving an unprecedented level of performance. This advancement unlocks significant opportunities for the life sciences sector, especially for biotech and pharma in vaccine development, gene editing, and more. Our team has also established a robust operational infrastructure essential for our upcoming commercial expansion.”
Dr. Ybert’s move to CSO reflects the company’s focus on scientific innovation. In his new role, he will continue to lead research efforts supporting the proprietary enzymatic DNA synthesis platform.
Expressing his enthusiasm for this transition, Dr. Ybert stated, “Since DNA Script’s founding, we have secured over €265 million in equity financing, filed more than 150 patent applications, and generated over €20 million in revenue through our SYNTAX product line and collaborations with top organizations globally. As we advance our platform for the next phase of growth, I am excited to concentrate on the scientific innovation that defines our company. With Marc’s leadership, DNA Script is poised to leverage our scientific breakthroughs and expand our global footprint.
About DNA Script
DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful, and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional chemical DNA synthesis called enzymatic DNA synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.
